Clinical trials: Impaired Renal Function
- Condition Impaired Renal Function
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Renal Impaired, Gilteritinib
A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function
The purpose of the study was to evaluate the pharmacokinetics of a single oral dose of gilteritinib in male and female participants with severe renal impairment compared to healthy male and female participants with normal renal…
- Conditions
- Renal Impaired, Gilteritinib, Normal Renal Function, Pharmacokinetics of ASP2215
- Trial name
- NCT04699877
- Testing
- Gilteritinib
- Where
- 4 sites in United States, Bulgaria
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Patients With Impaired Renal Function
Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function
The objective of this study is to compare the pharmacokinetics of ASP015K in patients with impaired renal function and subjects with normal renal function.
- Trial name
- NCT02603497
- Testing
- ASP015K
- Where
- 2 sites in Japan
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Impaired Renal Function
Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
Shire is developing SSP-004184 (FBS0701), a novel iron chelator , for the treatment of chronic iron overload in patients with transfusion-dependent hereditary and acquired anemias.
- Trial name
- NCT01716455
- Testing
- SSP-004184
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Shire
Impaired Renal Function
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
Phase 1 - Pharmacokinetics in Patients with Impaired Renal Function
- Trial name
- NCT03776539
- Testing
- ELX-02
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eloxx Pharmaceuticals, Inc.
PK Properties Of Gabapentin In Subjects With Impaired Renal Function
An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis
To confirm the pharmacokinetics following administration of gabapentin to Japanese subjects with renal impairment, compare the results to Western study results and confirm the adaptive possibility of dose adjustment in US package…
- Trial name
- NCT00584779
- Testing
- Gabapentin
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Normal Renal Function, Impaired Renal Function
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
The purpose of this study is to characterize the PK and safety profile of LEE011 following a single oral dose in adult subjects with various degrees of renal impairment compared to a matched group of healthy subjects with normal…
- Trial name
- NCT02431481
- Testing
- LEE011
- Where
- 4 sites in United States, Bulgaria and 2 more
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Subjects With Impaired Renal Function and Healthy Subjects
A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function
The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function.
- Trial name
- NCT04414852
- Testing
- Apatinib Mesylate
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Volunteers, Impaired Renal Function
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
This is a Phase 1, multicentric, open-label,two arms to assess and compare the effect of single oral administration of MD1003 on the pharmacokinetic parameters in renal impaired patients and healthy subjects with normal renal…
- Trial name
- NCT04252430
- Testing
- MD1003
- Where
- 5 sites in France, Hungary
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MedDay Pharmaceuticals SA
Impaired Renal Function
Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
This is a single-center evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Renal Function.
- Trial name
- NCT04179630
- Testing
- Aldafermin (NGM282)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Normal Renal Function, Impaired Renal Function
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
For subjects with normal renal function or severely impaired renal function, this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma and urine.
- Trial name
- NCT02965040
- Testing
- Roxadustat
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Normal and Impaired Renal Function
A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function
This study is a Phase 1, open-label, parallel group, multiple dose study, in subjects over 18 years, to evaluate the safety, tolerability, and pharmacokinetics of one-hour intravenous infusion of MTP-131 administered for 7…
- Trial name
- NCT02436447
- Testing
- MTP-131
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Stealth BioTherapeutics Inc.
Normal Renal Function, Mildly Impaired Renal Function
Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function
To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).
- Conditions
- Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function
- Trial name
- NCT00543075
- Testing
- Genasense (oblimersen, G3139)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Genta Incorporated